We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AT-527

News List

Atea to study AT-527 as monotherapy and in combination for Covid-19 Pharmaceutical-Technology
December 16, 2021
Atea Pharmaceuticals has announced an update to its strategy to use AT-527 as a single agent and in combination against the SARS-CoV-2 virus and the new variants.
Atea to terminate Covid-19 drug development deal with Roche Pharmaceutical-Technology
November 18, 2021
Atea Pharmaceuticals has announced plans to terminate a strategic partnership with Roche to co-develop the former’s experimental oral direct-acting antiviral pill, AT-527, to treat Covid-19.
Atea reports positive Phase I data from oral antiviral agent trial for Covid-19 pharmaceutical-technology
March 09, 2021
Atea Pharmaceuticals has reported that results from the Phase I study of oral antiviral agent AT-527 showed it was well tolerated with a favourable safety profile in healthy volunteers.
Roche, Atea Pharma to Develop Potential Oral COVID-19 Treatment contractpharma
October 23, 2020
Roche and Atea Pharmaceuticals, Inc. have partnered to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to treat COVID-19.